Does the 1:1:1 Transfusion Ratio Mortality Benefit Hold True in Ultra-massive Transfusion? A Study From the Product (Patient Related Outcomes During Ultra-massive transfusion multi-Center Trial) Consortium.
Meyer CH, Grady Z, Smith RN, Moran TP, Rowh M, Zhang A, Harfouche MN, Greiffenstein P, Trinh S, Inaba K, Nekooei N, Filiberto DM, Jones Sayyid CE, Gutierrez A, Meizoso J, Risinger WB, Smith JW, Jacovides CL, Trausch ED, McNickle AG, Kumar A, Choron RL, Ross SW, Sanderfer VC, Sciarretta JD, Nguyen JH.
Meyer CH, et al. Among authors: kumar a.
Am Surg. 2025 Jul 4:31348251358431. doi: 10.1177/00031348251358431. Online ahead of print.
Am Surg. 2025.
PMID: 40614227